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Abstract Several members of the RNase A superfamily are
endowed with antitumor activity, showing selective cytotoxicity
toward several tumor cell lines. One of these is onconase, the
smallest member of the RNase A superfamily, which is at present
undergoing phase III clinical trials. We report here the
expression of recombinant onconase in Escherichia coli inclusion
bodies, the correct processing of the protein, followed by its
purification in high yields. The recombinant protein has
biological and catalytic properties identical to those of the
natural enzyme.
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1. Introduction
Members of the RNase A superfamily are endowed with
antitumor activity, showing selective cytotoxicity toward sev-
eral tumor cell lines. Among these are bovine seminal ribonu-
clease (BS-RNase) from bull semen, and onconase (ONC)
from oocytes of Rana pipiens [1]. These proteins have been
extensively studied because of their potential as antitumor
drugs, and onconase has reached phase III clinical trials [2].
Therapeutic use of onconase as an antitumor drug would
greatly bene¢t from the availability of the biologically active
recombinant protein produced in good yields. A mutant re-
combinant onconase has been obtained by Boix et al. [3], with
leucine replacing methionine at position 23 ((M23L)-ONC).
However, the mutant showed a reduced antitumor action
compared to that of native onconase [3,4], and the yield of
the protein was not clearly stated.
More recently, Leland et al. [5] have described an Esche-
richia coli system for the expression and secretion of mature
recombinant onconase, identical to the natural protein. Sur-
prisingly, the protein was found to be processed in the cyto-
plasm and found to segregate in inclusion bodies. After ex-
traction, refolding and puri¢cation, its catalytic activity on
poly(C), and its cytotoxicity on K562 cells were found to be
comparable to those of native onconase. Yields of 5^50 mg/l
culture were given, and the protein was further characterized.
Here we report an e¡ective expression and puri¢cation sys-
tem in high yields of recombinant onconase. The protein has
been characterized in its cytotoxic activity and found to be
identical to the natural protein when assayed on myelogenous
leukemia cells K562, and on malignant, SV40-transformed
SVT2. Moreover, also its catalytic properties are identical to
those reported for the natural enzyme [3].
2. Materials and methods
2.1. Materials
Onconase puri¢ed from oocytes of R. pipiens was kindly provided
by Dr. Kuslima Shogen (Alfacell Corp., USA). Plasmid pET22b(+)
and E. coli strain BL21(DE3) were from AMS Biotechnology. E. coli
strain JM101 was purchased from Boehringer. RNase A (Type XIIA)
was purchased from Sigma-Aldrich, Milano, Italy; labeled oligonu-
cleotides from Amersham. The Wizard DNA puri¢cation kit for elu-
tion of DNA fragments from agarose gel, enzymes and other reagents
for DNA manipulation were from Promega Biotech.
2.2. General procedures
Bacterial cultures, plasmid puri¢cations and transformations were
performed according to Sambrook et al. [6]. Double-strand DNA was
sequenced with the dideoxy method of Sanger et al. [7], carried out
with a Sequenase version II Kit (Amersham) with deoxynucleotide
triphosphates purchased from Pharmacia.
2.3. Recombinant DNA methodologies
The cDNA encoding Met(31)(Q1E)-ONC cloned between Nde1
and BamH1 sites of vector pET11d, kindly provided by Dr. R.J.
Youle (National Institute of Neurological Disorders and Stroke,
NIH), was subcloned into vector pET22b(+) between the same restric-
tion sites. Oligonucleotide mediated site directed mutagenesis accord-
ing to Kunkel [8] was used to restore the glutamine residue at position
1, and yield the cDNA encoding recombinant onconase. This latter
cDNA was further mutated to replace methionine residue at position
23, yielding the coding sequence for mutant (M23L)-ONC. Protein
expression was carried out after transformation of E. coli strain
BL21(DE3) with the appropriate plasmid. Cells were grown to about
3.5^4 OD at 600 nm in TB medium. Expression was induced by IPTG
at a ¢nal concentration of 0.4 mM and cells were collected after over-
night induction.
2.4. Cell cultures
Human chronic myelogenous leukemia cells K562, malignant,
SV40-transformed SVT2 ¢broblasts and the parental non-transformed
Balb/C 3T3 line were obtained from ATCC (Richmond, VA, USA),
and cultured in 24-well plates at a density of 50U103/ml of Dulbecco’s
modi¢ed Eagle’s medium, supplemented with glutamine, penicillin,
streptomycin, and 10% fetal calf serum. The RNases being tested
were added to the cells before plating, and cells were counted after
time intervals as indicated, allowing at least three to four rounds of
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replication in the control cultures. Because of their morphology, via-
ble K562 cells were counted with the trypan blue exclusion test.
2.5. Other methods
Protein sequence determinations were performed on an Applied
Biosystems sequenator (model 473A), connected on-line with a high
performance liquid chromatography apparatus for identi¢cation of
phenylthiohydantoins. The electrospray mass spectrometric (ES-MS)
analyses were performed using an Api-100 triple quadrupole mass
spectrometer (Perkin Elmer) equipped with an electrospray ion
source, at CEINGE Biotecnologie Avanzate (Naples, Italy). RNase
activity on yeast RNA was assayed with the method of Kunitz [9], or
by the precipitation assay [10]. SDS-PAGE was carried out according
to Laemmli [11].
3. Results and discussion
3.1. Expression and puri¢cation of recombinant onconase and
of mutein (M23L)-ONC
Recombinant onconase and its variant (M23L)-ONC were
expressed according to the procedure described in Section 2.
An SDS-PAGE analysis of induced and non-induced cells
extracted in SDS containing 2-mercaptoethanol showed that
in both cultures a protein of about 11 kDa was produced only
in the IPTG-induced cells (Fig. 1). These proteins were tenta-
tively identi¢ed with onconase and (M23L)-ONC, respec-
tively. Yields were of about 100^120 mg of protein/l of bacte-
rial culture, on the basis of a densitometric scanning of the
electrophoretic pro¢le. SDS-PAGE analysis after sonication
of a cell pellet revealed (data not shown) that proteins of
interest were present only in the insoluble fraction, hence pre-
sumably contained in cell inclusion bodies.
For preparative purposes, cells from 1 l culture were sus-
pended in 10 ml of bu¡er A (50 mM Tris-acetate, pH 8.4,
containing 10 mM EDTA), and sonicated (6U1 min cycle).
The suspension was then centrifuged at 17 400Ug for 60 min
at 4‡C. The cell pellet was freed from membrane proteins by
two washes in 0.1 M Tris-acetate, pH 8.4, containing 10 mM
EDTA, 2% Triton X-100 and 2 M urea, followed by repeated
washes in 0.1 M Tris pH 8.4, containing 10 mM EDTA to
eliminate traces of Triton and urea. This procedure eliminated
several contaminant proteins and cellular debris entrapped in
inclusion body pellets.
Inclusion bodies were then dissolved in 0.1 M Tris-acetate
pH 8.4, 10 mM EDTA, 6 M guanidine-Cl and 25 mM DTT,
purged with N2, and incubated at 37‡C for 3 h. The protein
solution was dialyzed overnight versus 0.1 M acetic acid at
4‡C. Any insoluble material was removed by centrifugation
and the supernatant, containing the RNases in the completely
reduced form, was lyophilized.
In vitro renaturation of recombinant onconase and
(M23L)-ONC was carried out as described [12]. The refolded
proteins, with an N-terminal methionine as determined by
Edman sequencing, had a low catalytic activity as reported
by Boix et al. [3]. Removal of the N-terminal residue was
attempted using Aeromonas proteolytica aminopeptidase
(AAP) [13], which proved to be useful in the removal of
Met-1 from other RNases such as angiogenin [14] and BS-
RNase [15]. The attempt met with no success. A likely explan-
ation for this result can be drawn from the three-dimensional
structure of onconase. The protein has an N-terminal region
shorter than those of homologous RNases, and closer to its
main body [16]. Thus steric hindrance could explain the in-
ability of AAP to cleave the N-terminal residue. On the basis
of this hypothesis we tried to remove Met-1 from the unfolded
proteins prior to folding. In order to maintain onconase and
(M23L)-ONC in the unfolded conformation suitable to the
activity of AAP, the lyophilized reduced and denatured pro-
teins were dissolved at 2 mg/ml in 0.2 M Tris-acetate pH 9.3,
containing 10 mM EDTA, 6 M guanidine-Cl. Cystamine was
added at 0.2 M ¢nal concentration, and the reaction mixture
was incubated at 37‡C for 20 h to promote the formation of
mixed disul¢des between cysteine residues of the proteins and
cysteamine. It should be noted that cystamine was chosen
instead of other disul¢de small molecules such as oxidized
glutathione, because of its higher solubility and its positive
charge, which could improve the solubility of the polypeptide
chain. The samples were then dialyzed versus 0.1 M acetic
acid and lyophilized. Lyophilized material was dissolved in
4 M guanidine-Cl, and diluted ten times in 0.2 M potassium
phosphate pH 7.2, containing 0.5 mM ZnSO4. AAP was
added to the solution in a molar ratio 1:2000, and the mixture
incubated at 37‡C. The reaction was followed by Edman se-
quencing. The N-terminal sequence of the untreated recombi-
nant onconase was found, as expected, to be NH2-Met-Gln-
Asp-. After 10 h of incubation only a small fraction of protein
presented an N-terminal Met, while in an even smaller frac-
tion N-terminal Gln was detected. After 15 h of incubation
the protein was found to be totally resistant to the Edman
reaction. These ¢ndings indicate that the removal of the N-
terminal Met by AAP from the recombinant protein was com-
plete, and that upon the removal the exposed Gln completely
cyclized into pyroglutamate. This result was con¢rmed by the
data from an electrospray mass spectrometry analysis which
yielded an MW of 12 430.13 þ 0.83 Da, corresponding to pro-
cessed onconase, with a pyroglutamyl residue, and coupled to
eight molecules of cysteamine (calculated MW = 12 429.6).
Renaturation of the derivatized proteins was achieved by
diluting samples in 0.1 M potassium phosphate pH 7.8, 10 mM
EDTA, followed by addition of a redox mixture containing
3 mM cysteamine and 0.6 mM cystamine. Maximal renatura-
tion was obtained after 12 h at room temperature, as judged
by recovery of the RNase activity, measured by the precipi-
tation assay [10] using yeast RNA as a substrate. Renatured
proteins were further puri¢ed by a single a⁄nity chromato-
graphic step on Blue-Agarose. Samples were loaded on the
Fig. 1. SDS-PAGE electrophoresis in 15% polyacrylamide gel under
reducing conditions of: cell lysates from non-induced (lane 2), and
induced (lane 3) E. coli clones expressing r-ONC; cell lysates from
non-induced (lane 5), and induced (lane 6) E. coli clones expressing
(M23L)-ONC. In lanes 4 and 7 are shown r-ONC and (M23L)-
ONC, respectively, puri¢ed after a⁄nity chromatography on Blue-
Agarose. In lane 1 RNase A, run as a control.
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column (15U170 mm) in 50 mM sodium acetate pH 5.0;
elution was performed with an NaCl gradient (0 to 1 M,
400 ml), at 10 ml/h. The proteins recovered from Blue-Aga-
rose were found to be homogeneous, as judged by SDS-PAGE
(Fig. 1).
Molecular weights of recombinant proteins were deter-
mined by ES-MS. The molecular mass of r-ONC was found
to be 11 821.53 þ 1.52 Da, in good agreement with that ex-
pected for onconase with 6Glu-1 (11 820.54 Da). The molec-
ular weight of mutant (M23L)-ONC was found to be
11 802.63 þ 1.15 Da, i.e. that expected for mutant (M23L)-
ONC with 6Glu-1 (calculated MW = 11 801.6).
The ¢nal yield for both recombinant onconase and the mu-
tant (M23L)-ONC was about 40 mg per liter of culture.
3.2. Catalytic activity
Onconase prefers yeast RNA and poly(U), as judged by its
speci¢c activity values. Moreover, on both substrates it is
slightly more active at pH 5.5 than at pH 7.5 [3]. Table 1
reports the activity on yeast RNA at pH 5.5 for RNase A,
onconase, recombinant onconase and (M23L)-ONC. r-Onco-
nase prepared with the procedure described in the present
paper is catalytically undistinguishable from the natural pro-
tein. Moreover, r-ONC is about 230-fold less active than
RNase A in 0.2 M sodium acetate, in good agreement with
previous data [3]. When the same experiments were carried
out at lower ionic strength, in 0.1 M sodium acetate, pH
5.5, r-ONC was found to be only 27-fold less active than
RNase A. As Boix et al. [3] have reported that onconase
catalytic activity is not in£uenced by ionic strength between
0.1 M and 0.2 M NaCl at pH 7.5, we decided to explore the
e¡ect of ionic strength at pH 5.5. In Fig. 2 RNase activity of
the three is plotted as a function of NaCl concentration.
While RNase A activity increases with ionic strength, onco-
nase activity sharply decreases between 0.1 M (50 mM sodium
acetate plus NaCl 50 mM) and 0.25 M (50 mM sodium ace-
tate plus 200 mM NaCl) salt concentration. It should also be
noted that a comparison of the data in Table 1, with those
reported in Fig. 2 shows that NaCl and sodium acetate have a
similar inhibitory e¡ect on onconase and (M23L)-ONC. In
fact, both proteins have the same activity in 0.2 M sodium
acetate and in 0.05 M sodium acetate containing 0.15 M
NaCl.
Furthermore, as shown in Table 1 and in Fig. 2, catalytic
activity on yeast RNA of mutant (M23L)-ONC is surprisingly
high, compared to that of onconase, and is less sensitive to
ionic strength. In fact, it is 5-fold more active than the wild-
type enzyme at low ionic strength, and 15-fold more active at
high ionic strength. These data are also to be compared with
those reported by Boix. (M23L)-ONC was found to be only
1.7-fold more active than n-ONC on poly(U), at pH 5.5 in 0.2
M sodium acetate [3]. In our opinion this di¡erence might be
due either to di¡erent substrate speci¢city of ONC and
(M23L)-ONC for RNA and poly(U), or to the di¡erent pro-
cedures for removing the N-terminal methionine from the
recombinant proteins (see below).
The e¡ect of the mutation M23L in increasing the catalytic
activity of onconase is quite surprising as Met and Leu are
considered very similar residues for hydrophobicity, size and
K-helix preference. Moreover, Met-23 is in the hydrophobic
core of the protein [17] and apparently does not directly con-
tribute to the structure of the active site. Preliminary calori-
metric studies (F. Catanzano et al., manuscript in prepara-
tion), show that onconase is an exceptionally stable enzyme
with a very high melting temperature at pH 6, whereas
(M23L)-ONC has a lower Tm under the same conditions.
Several examples are available [18] of mutations which de-
crease thermostability and increase catalytic activity. Thus,
the hypothesis can be advanced that replacement of leucine
for methionine at position 23 of onconase decreases the stabil-
ity of the protein, hence increasing its £exibility and, as a
consequence, its catalytic activity. However, further physico-
chemical studies and onconase mutants are required to test
this hypothesis.
3.3. Antitumor activity
The antitumor activity of onconase, recombinant onconase
and (M23L)-ONC was assayed on two very di¡erent tumor
cell lines, SVT2 malignant ¢broblasts, extensively used in the
case of other ribonucleases [19,20], and K562 erythroleukemic
Table 1
Catalytic activity on yeast RNA of onconase (n-ONC), recombinant
onconase (r-ONC), and (M23L)-ONC, at di¡erent sodium acetate
concentrations
[Na acetate]
0.05 M 0.1 M 0.2 M
Speci¢c activitya
RNase A 100 þ 3 288 þ 20 352 þ 17
r-ONC 9.1 þ 0.6 10.9 þ 0.2 1.7 þ 0.1
n-ONC 9.2 þ 0.16 11.0 þ 0.2 1.7 þ 0.2
(M23L)-ONC 50.6 þ 2.8 54.9 þ 1.9 22.2 þ 2.8
aRelative to RNase A speci¢c activity at 25‡C in 0.05 M sodium
acetate pH 5.5 taken as 100. The activity of RNase A ranged be-
tween 99 and 110 Kunitz units/mg of protein.
Fig. 2. E¡ect of NaCl on the catalytic activity on yeast RNA of
r-ONC (a), (M23L)-ONC (b), and RNase A (E). All assays were
performed in 0.05 M sodium acetate, pH 5.5, in the presence of the
indicated NaCl concentration.
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cells, used in the case of recombinant onconase [5]. Recombi-
nant onconase and (M23L)-ONC were also compared to BS-
RNase, a mammalian antitumor RNase.
On SVT2 cells onconase and recombinant onconase showed
very similar activity, con¢rming the identity of the properties
of the recombinant protein with those of the natural one. The
same biological activity was displayed by the mutant (M23L)-
ONC and by BS-RNase (Fig. 3A). On the other hand, on
K562 cells, onconase, recombinant onconase, and (M23L)-
ONC were more active than BS-RNase. The IC50 (the protein
concentration for 50% growth inhibition) was higher (about
25 Wg/ml) for onconase and recombinant onconase than that
reported by Leland et al. (6 Wg/ml) [5]. However, it should be
taken into account that Leland et al. determined the IC50
measuring 3H-timidine incorporation, a more sensitive test
than the measure of cell survival.
3.4. Concluding remarks
The availability of a recombinant protein, identical to its
cognate natural counterpart in chemical and biological prop-
erties, is a powerful tool for the study of the molecule itself.
Moreover, in the case that the protein has biologically rele-
vant properties, as it is the case of onconase, endowed with a
potent antitumor action, the recombinant production of the
protein gives an easier and very rich source for its use as a
potential drug.
The expression system described in the present paper is such
a source, because it allows the reproducible puri¢cation of
relatively large amounts (more than 40 mg/l of bacterial cul-
ture) of recombinant onconase with an antitumor activity un-
distinguishable from that of the natural protein. Moreover,
with the procedure reported here a processed mature protein
is obtained which does not su¡er from the reduced antitumor
activity shown by the recombinant molecule prepared with
previous procedures [3]. This di¡erence might be attributed
to damages to the protein structure caused by the treatment
(CNBr in HCl) used by Boix et al. for removing the N-termi-
nal methionine from the recombinant protein, although the
mutant had the expected molecular mass.
Our data con¢rm and expand the observation that the mu-
tein (M23L)-ONC is catalytically more active than native and
recombinant onconase. This data, together with the prelimi-
nary reports on the lower thermal stability of the mutant, can
lead to the hypothesis that replacement of leucine for methio-
nine at position 23 of onconase increases its £exibility and, as
a consequence, its catalytic activity.
The data presented in the present paper shed also light on
the relationships between catalytic activity and antitumor ac-
tion in onconase. The mutein (M23L)-ONC is a better cata-
lyst than onconase but not a better antitumor agent. It has
been widely demonstrated that catalytic activity is one of the
factors determining the antitumor activity of a ribonuclease
[1]. Recently [21], a hypothesis has been advanced on the
‘mosaic’ nature of the selective cytotoxicity of ribonucleases,
which depends on several extra- and intra-cellular steps, such
as binding at the cell surface, internalization, progression to
the cytosol, RNA degradation and resistance to the cytosolic
RNase inhibitor. Thus, on the basis of the mosaic hypothesis
it should not be surprising that catalytic activity and antitu-
mor action do not parallel in the case of (M23L)-ONC. This
would indicate, at least for SVT2 and K562 cells, that the
intrinsic catalytic e⁄ciency may not be the limiting step in
the cytotoxic action of a ribonuclease.
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